Immunizations and Vaccines

General Information and Programs

Top of Page

Research

2012

Adults Need Immunizations, Too (6/30/2012)
Your need for immunizations doesn't end when you reach adulthood. Protect yourself and your loved ones from vaccine-preventable diseases. Be the example!

Updated HPV Vaccine (Gardasil®) What You Need to Know (3/30/2012)
This updated information sheet answers eight questions: what is HPV, why get vaccinated, who should get this HPV vaccine and when, why should some people not get the vaccine or wait, what are the risks from this vaccine, what if there is a moderate or severe reaction, what is the national vaccine injury compensation program, and how can I learn more.

Vaccines Help Protect Travelers of All Ages (3/302012)
Travel within the U.S. or to other countries can be an opportunity for volunteerism or work, fun and relaxation, but also exposure to disease. Make sure you and your loved ones are protected against vaccine-preventable diseases that may be only a plane ride away.

Recommended Adult Immunization Schedule - United States, 2012 (3/8/2012)
In October 2011, ACIP approved the adult immunization schedule for 2012, which includes several changes from 2011.

Adult Vaccination Coverage - United States, 2010 (3/8/2012)
Compared with results of the 2009 NHIS survey (1), increases in coverage were observed only for Tdap vaccination for persons aged 19-64 years, zoster vaccination among persons aged ≥60 years, and ≥1 dose HPV vaccination in women aged 19-26 years; coverage for the other vaccines was unchanged at <70%.

2011

Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 through 59 Years (12/8/2011)
Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older (1). In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years (2). In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.

Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged< 12 Months-Advisory Committee on Immunization Practies (ACIP), 2011 (11/3/2011)
On June 22, 2011, the Advisory Committee on Immunization Practices made recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) in unvaccinated pregnant women and updated recommendations on cocooning and special situations. This report summarizes data considered and conclusions made by ACIP and provides guidance for implementing its recommendations.

Influenza Vaccination Coverage Among Pregnant Women - United States, 2010-11 Influenza Season (9/16/2011)
Results from this survey indicate that the record high influenza vaccination levels among pregnant women reported for the previous influenza season (2009-10) were sustained during the 2010-11 season.

Preteens and Teens Need Vaccines Too! (5/20/2011)
The preteen and teen vaccines not only help protect them, but also their friends, community and family members. There are four vaccines recommended for preteens and teens. All kids should get a flu vaccine every year, and the three other vaccines should be given starting when kids are 11 to 12 years old.

Top of Page

2010

Vaccinia Virus Infection After Sexual Contact with a Military Smallpox Vaccinee - Washington, 2010 (7/30/10)
This report describes a patient's clinical course and the associated epidemiologic investigation of contact transmission of vaccinia virus from sexual contact.

Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010
The 2010 influenza recommendations include new and updated information. Vaccination and health-care providers should be alert to announcements of recommendation updates and should check the CDC influenza website periodically for additional information.

FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP) (5/28/10)
In anticipation of FDA licensure of HPV2, ACIP reviewed data on the immunogenicity, efficacy, and safety of HPV2, as well as information on HPV4. At its October 21, 2009, meeting, ACIP approved updated recommendations for use of HPV vaccines in females.

Recommended Adult Immunization Schedule - United States, 2010 (2/24/10)
In October 2009, the Advisory Committee on Immunization Practices approved the Adult Immunization Schedule for 2010, which includes several changes. A bivalent human papillomavirus vaccine (HPV2) was licensed for use in females in October 2009. ACIP recommends vaccination of females with either HPV2 or the quadrivalent human papillomavirus vaccine (HPV4). HPV4 was licensed for use in males in October 2009, and ACIP issued a permissive recommendation for use in males. Other changes in publication.

Transmission of Yellow Fever Vaccine Virus Through Breast-Feeding - Brazil, 2009 (2/24/10)
This report describes the first laboratory-confirmed case of yellow fever vaccine--associated neurologic disease occurring in an infant secondary to the transmission of yellow fever vaccine virus through breast milk. The infant described in this report also is the youngest reported case of yellow fever vaccine--associated neurologic disease.

Top of Page

2009

Receipt of Influenza Vaccine during Pregnancy among Women With Live Births- Georgia and Rhode Island, 2004-2007 (10/13/09)
This report showed that in Georgia, the prevalence of influenza vaccination during the woman's most recent pregnancy increased from 10.4 percent in 2004 to 15.5 percent in 2006. In Rhode Island, vaccination prevalence increased from 21.9 percent in 2004 to 33.4 percent in 2007. Increased efforts are needed to assess vaccine coverage during pregnancy and to educate providers and pregnant women.

Nation′s Teen Vaccination Coverage Increasing, Variability Observed by Area, Race/Ethnicity, and Poverty Status (10/13/09)
This survey found that, compared to 2007, there was a substantial increase in the percentage of teens who had received the recommended vaccines. Specifically, coverage went up about 12 percentage points for girls who received at least one dose of HPV4, to about 37 percent, and coverage for the recommended 3 doses of HPV4 was about 18 percent. 

Use of Influenza A (H1N1) 2009 Monovalent Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 (9/30/09)
Five initial target groups have been identified for vaccination efforts. Priorities have been established for a subset of persons within the initial target groups in the event that initial vaccine availability is unable to meet demand. Guidance is provided on use of vaccine in other adult population groups as vaccine availability increases.

2009 H1N1 Influenza Vaccine and Pregnant Women (9/30/09)
Questions and answers about 2009 H1N1 Influenza Vaccine and Pregnant Women.

Questions and Answers: Use of Antiviral Medicines for the Treatment and Prevention of Flu among Pregnant Women for the 2009-2010 Season (9/30/09)
Pregnant women who are healthy have had severe illness from the 2009 H1N1 flu (also called “swine flu”). Compared with people in general, pregnant women with 2009 H1N1 flu have been more likely to be admitted to hospitals, and some have died.  CDC advises doctors to give antiviral medicines that treat 2009 H1N1 flu to pregnant women who have symptoms of flu.

Updated Interim Recommendations for Obstetric Health Care Providers Related to Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season (9/30/09)
Pregnant women are at higher risk for severe complications and death from influenza, including both 2009 H1N1 influenza and seasonal influenza.  Treatment with oseltamivir (Tamiflu®) or zanamivir (Relenza®) is recommended for pregnant women with suspected or confirmed influenza and can be taken during any trimester of pregnancy. The duration of antiviral treatment is 5 days.

Nation′s Teen Vaccination Coverage Increasing, Variability Observed By Area, Race/Ethnicity, and Poverty Status (9/30/09)
The National Immunization Survey estimates the proportion of teens aged 13 through 17 years who have received six recommended vaccines by the time they are surveyed. The survey found that, compared to 2007, there was a substantial increase in the percentage of teens who had received the recommended vaccines. Specifically: coverage went up about 10 percentage points for a dose of Tdap and a dose of MCV4, reaching about 40 percent for each vaccine; and  coverage went up about 12 percentage points for girls who received at least one dose of HPV4, to about 37 percent, and coverage for the recommended 3 doses of HPV4 was about 18 percent.

H1N1 Vaccine Questions? ...ask Dr. Anne (08/31/09)
In this podcast (or watch the video), learn about the H1N1 flu vaccine and how you can protect your family. Created: 8/20/2009

Native American Pre-teen Vaccine Campaign (8/30/09)
The Pre-Teen Vaccine Campaign includes posters, flyers, web buttons, and PSA's that educate parents and providers about recommended pre-teen vaccines and the 11 and 12 year old medical check-up. Materials are now available for parents and caregivers of Native American pre-teens. Materials, created after extensive audience research, are also available in English and Spanish. 

CDC Advisors Make Recommendations for Use of Vaccine against Novel H1N1 (8/10/09)
CDC's Advisory Committee on Immunization Practices developed recommendations on who should receive vaccine against novel influenza A (H1N1) when it becomes available. Five key priority populations include pregnant women and people who live with or care for children younger than 6 months of age.

HPV Vaccine Attitudes and Practices Among Primary Care Providers in Appalachian Pennsylvania (3/30/09)
The prevalence of offering the vaccine against human papillomavirus was high in this area of Appalachian Pennsylvania. Future interventions may focus on community education because the vaccine is available from most providers.

Recommended Immunization Schedules for Persons Aged 0 Through 18 Years - United States, 2009 (1/30/09)
The Advisory Committee on Immunization Practices annually publishes immunization schedules that summarize recommendations for currently licensed vaccines for children aged 18 years and younger. One of the changes to the previous schedule is as follows: Catch-up vaccination with human papillomavirus vaccine is clarified. Routine dosing intervals should be used for series catch-up (i.e., the second and third doses should be administered 2 and 6 months after the first dose). The third dose should be given at least 24 weeks after the first dose.

Human Papillomavirus (HPV) Vaccine Safety (1/27/09)
This page provides links to information on HPV vaccine safety, HPV vaccine, and disease information.

Top of Page